Imara, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9). PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule. IMR-687 is in Phase IIb clinical development for the treatment of sickle cell disease (SCD) and beta- thalassemia. It is also focused on initiating a Phase II clinical trial of IMR-687 in heart failure with preserved ejection fraction (HFpEF). The Company is also focused on development of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2-related factor 2 (Nrf2).
Number of employees: 6
IMARA 
